Company Overview

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is a science-led global healthcare company with a purpose to help people do more, feel better, live longer.

People are at the heart of everything the company do. The company aim to bring differentiated, high-quality and high performing healthcare products to those who need them with its global businesses, scientific and technical know-how and talented people.1

Bringing innovative products and improving access to them is critical to helping build stronger, healthier communities. The company leverage its legacy of over 90 years in India to help transform people’s health through its extensive product portfolio that includes prescription medicines and vaccines. GlaxoSmithKline Pharmaceuticals is the leaders in anti-infectives and dermatology in the pharmaceuticals industry and in vaccines too GlaxoSmithKline Pharmaceuticals is the leaders in the private segment.

Manufacturing facility in Nashik

Inaugurated in 1983, Nashik factory is situated on 47 acres of land in Ambad industrial belt. The facility manufactures tablets, creams and ointments and has a committed workforce of over 800 people. The facility is committed to conserving natural resources and ensuring operational safety in all its processes. The site ensures its sustainability through energy conservation and environment friendly processes to manufacture high quality affordable products. It strives to automate operations by implementing indigenously developed technology, thus improving productivity and efficiency. The facility has received various accolades in the areas of operational safety, environment protection, energy and water conservation and ergonomics.2

The new Eltroxin manufacturing facility in its current Nashik site became operational recently.


Global R&D support groups in Bengaluru, Karnataka

Global Regulatory Platforms and Delivery (GRPD): GRPD is a regulatory affairs function that brings together critical capabilities for GSK, such as regulatory dossier production, regulatory life cycle management, global labeling and regulatory information management.

Clinical Development Operations Centre (CDOC) : CDOC works on data handling, study set-up, scientific and public disclosure, biometrics, quality risk management and clinical project management.

Biostatistics India : Biostatistics team provides statistical and SAS programming support to clinical and epidemiology studies within GSK’s research and development department.

Safety Sciences India (SSI) : The SSI team is an enterprise platform that is involved with safety surveillance activities for all GSK generic products and some of the consumer health products. The team performs global literature search to screen articles for potential ICSRs/Articles of interest, involved in reconciliation of safety data exchange agreements and systems support.


The GSK India product portfolio includes prescription medicines and vaccines. The company's prescription medicines range across therapeutic areas and the company also offer a range of vaccines for prevention of life-threatening diseases.3

GlaxoSmithKline Pharmaceuticals is committed to Research and Development of medicines that will improve the quality of life of people around the world and truly make a difference to patients. GlaxoSmithKline Pharmaceuticals has submitted several applications for New Products in India to the CDSCO (Central Drugs Standard Control Organization), Ministry of Health and Family Welfare, Government of India. All new products and indications approved for the company will be beneficial to Indian patients.


The company produce medicines for the treatment of major disease areas such as asthma, infectious diseases, mental health and digestive conditions.


GlaxoSmithKline Pharmaceuticals is a leader in the important area of vaccines and are developing new treatments for cancer. In 2015 the company acquired Novartis’ global Vaccines business (excluding influenza vaccines).

Consumer Healthcare

GlaxoSmithKline Pharmaceuticals has a heritage that goes back more than 160 years, producing some of the world’s best-loved healthcare brands. In India, GSK has separate listed companies for its pharmaceutical and consumer businesses.

Business Overview


In 2019, the company continued to focus on delivering sustainable profitable growth. It accelerated growth in the anti-infectives, dermatology and anti-pyretic therapy areas, through a skill-enhanced sales force and improved engagement with healthcare professionals (HCPs). Trade channel was further strengthened through a dedicated salesforce and the company also initiated trade engagements leveraging cutting end technology. This led to an increase in share of voice for focus brands as also an increase in the number of touchpoints in HCP engagement.4

The company’s multi-channel marketing has also evolved, not just to enhance customer touchpoints but also to improve customer engagement. The company reached 21.6 million HCP touchpoints through various channels like webinars, e-mails, text messages, virtual calls and through the GSK Pro platform. The company’s major primary care brands are growing faster than the Indian Pharmaceutical Market. The Evolution Index for top brands are: Augmentin at 114; Ceftum at 106; Calpol at 108 and CCM at 107 (MAT Dec 2019, IQVIA, Internal MCM Dashboard).

The company maintained and consolidated its leadership in the dermatology segment in the Indian Pharmaceutical Market during the year. In addition to gaining share in topical antibiotics market, the company is now gaining consistently in the anti-fungal market with Zimig and Zoderm, two key anti-fungal medications. The BRIDGE (Bringing Insights from Dermatology Group of Experts) forum gained further traction and mobilized commitment amongst the dermatology fraternity with over 50 meets conducted last year, connecting 450 specialists from 17 cities in India.


In preventive healthcare, the company continues to be the No. 1 vaccine company in the self-pay segment with almost 40% value market share in represented segments. The vaccines self-pay market is currently estimated to be `2400 crores and is growing at around 10% (IMS MAT Mar 2020). Six of the company’s vaccines feature in the Top-20 list of vaccines in the selfpay market (IMS MAT Mar 2020). The company currently markets vaccines for varied age groups - infants, adolescents and adults.

Since its launch about eight years back, the company has distributed more than ten million (one crore) doses of Synflorix protecting kids against pneumococcal diseases. Infanrix Hexa (6-in-1 combination DTP vaccine), launched in April 2018, is already a market leader in the Inactivated Polio Vaccine (IPV) containing combination vaccine segment. In December 2019, the company launched Menveo (Quadrivalent Meningococcal Conjugate Vaccine). Menveo has demonstrated early success and currently has a 30% unit share within four months of its launch (IMS Mar 2020).

The company continues to promote maternal immunisation against pertussis with Boostrix. The company is partnering with Federation of Obstetric and Gynaecological Societies of India (FOGSI) and Indian Academy of Pediatrics (IAP), to drive awareness among women for vaccination against maternal and neonatal pertussis.

The company also launched an awareness campaign on vaccination for school-going kids who may have either missed childhood vaccines or may be due for certain vaccines.

Opportunities, risks, concerns and threats

The Covid-19 pandemic is re-defining the conventional way of business. It has also exposed sectoral vulnerabilities, forcing the policy-makers to take corrective measures that will benefit the industry in the long-term. Dependency on imported Active Pharmaceutical Ingredient(s) (APIs) is one such area. The recent government’s decision on promotion of domestic manufacturing of critical APIs and Key Starting Materials (KSMs) bodes well for the country.

A robust domestic supply shall also help greatly in stabilising the API prices.

The healthcare policy landscape in India is at an inflection point. The government has begun a fresh exercise to revise the National List of Essential Medicines (NLEM) hoping that it would result in better quality of medical care, better management of medicines and cost-effective use of healthcare resources. The government started the process in late 2019, and since then has had a series of stakeholder dialogues. Additionally, new regulations like the Personal Data Protection Bill 2019 and the E-Pharmacy Rules are expected to be introduced in the current financial year. The company is a part of various stakeholder discussions with the government and the relevant subject-matter committees on these and has been presenting the company’s perspectives on a regular basis.

The company is aligned with the government’s broader mandates on public health and its various programmes to reduce the disease burden of the country. The company’s existing commitment and support to the government on various public health mandates shall continue unabated and collaboration opportunities will continue to be explored to leverage mutual synergies for greater good.

Financial Highlights

May 18, 2020. GlaxoSmithKline Pharmaceuticals Limited declared its financial results for the quarter ended 31st March 2020. Revenue for the quarter came in at Rs 776 crores. Profit After Tax at Rs 138 crores recorded a growth of 12%.5

The full year reported revenue was at Rs 3225 crores, a growth of 3% (sales growth of 3%) versus last year. EBITDA for the year is 21% and is higher by 1% against the prior year.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said,

“Despite the headwinds caused by Covid-19 during Q4, I am pleased with its overall performance during the year. Keeping patient safety at the core, GSK continues to serve the patients through a dedicated workforce that has ensured continued production and supply of medicines across the country during such challenging circumstances. The company's investments into digital transformation have helped it immensely during these times to keep it connected to the healthcare professionals (HCPs) and pay closer attention to their needs.

In 2019, the company continued to focus on delivering sustainable profitable growth. The company witnessed an accelerated growth in the anti-infectives, dermatology and anti-pyretic therapy areas, through a skill-enhanced sales force and improved engagement with HCPs. The company's major primary care brands grew at a better rate than the Indian Pharmaceutical Market. The underlying Sales growth adjusting for tail-end brand rationalization and divestment is at a healthy 13% and its key brands continue to grow at +20%. The Board of Directors recommend a Dividend of Rs 40 per equity share which includes a special dividend of Rs. 20 per share for this year.

In preventive healthcare, GSK continues to be the No. 1 vaccines company in the self-pay segment with almost 40% value market share in represented segments. In December 2019, the company launched Menveo (Quadrivalent Meningococcal Conjugate Vaccine), which has demonstrated early success and within four months of its launch has a 30% unit share.

The company's Q3 and full year results were impacted due to the voluntary global recall of ranitidine products including Zinetac in India and trigger-based impairment charges primarily towards its manufacturing facility at Vemgal. GlaxoSmithKline Pharmaceuticals is currently exploring future options for the Vemgal facility including a potential sale of the site

The Q4 has presented to it an unprecedented challenge in the form of a global pandemic. At GSK, its core guiding principles remains employee safety and well-being, business continuity, and social responsibility. As the nation-wide lockdown is getting relaxed, GSK is swiftly adapting to news ways of working defined by self-assessment, social distancing and good hygiene practices. As a socially responsible corporate citizen, GlaxoSmithKline Pharmaceuticals has contributed essential medicines and PPEs to the state government of Maharashtra and have committed funds to the PM-CARES.”

GlaxoSmithKline Consolidated December 2020 Net Sales at Rs 857.20 crore, up 10.1% Y-o-Y 6

February 09, 2021; Reported Consolidated quarterly numbers for GlaxoSmithKline Pharmaceuticals are:

  • Net Sales at Rs 857.20 crore in December 2020 up 10.1% from Rs. 778.59 crore in December 2019.
  • Quarterly Net Profit at Rs. 156.51 crore in December 2020 up 123.67% from Rs. 661.16 crore in December 2019.
  • EBITDA stands at Rs. 219.53 crore in December 2020 up 55.82% from Rs. 140.89 crore in December 2019.
  • GlaxoSmithKline EPS has increased to Rs. 9.24 in December 2020 from Rs. - 39.03 in December 2019.


  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
Created by Asif Farooqui on 2020/08/10 12:42
This site is funded and maintained by